GO:0007409 axonogenesis: Neuronal Morphogenesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007409 axonogenesis is the biological process of de novo generation of a neuron's long process, including its terminal branched region, as defined by QuickGO.
• Axonogenesis is coordinated by neuron-specific alternative splicing programs, exemplified by the splicing regulator PTBP2, which controls the timing and fidelity of axon outgrowth.
• Axonogenesis is not restricted to development; it is reactivated in tumors such as adenoid cystic carcinoma, KRAS-mutant pancreatic cancer, and osteosarcoma, where it promotes progression and aggressiveness.
• CCL5 is essential for axonogenesis and neuronal restoration after brain injury, linking neuroimmune signaling to axonal regrowth.
• The maternal microbiome modulates fetal neurodevelopment, including axonogenesis-related processes, in mice, showing that environmental factors shape this process.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models are key tools for dissecting causal roles of axonogenesis genes in development and disease.
Description
GO:0007409 axonogenesis is the biological process by which a neuron generates a long process, the axon, including its terminal branched region, thereby establishing the structural basis for efferent (outgoing) action potential transmission from the cell body toward target cells. This process is fundamental to nervous system wiring and is coordinated by neuron-specific alternative splicing programs and splicing regulators such as PTBP2. Beyond development, axonogenesis has emerged as a pathological feature in multiple cancers, where it contributes to tumor progression and aggressiveness. Understanding axonogenesis therefore spans developmental neurobiology, neuroregeneration, and oncology. Researchers study axonogenesis to identify molecular drivers of neuronal morphogenesis, to understand how neuroimmune signals such as CCL5 support neuronal restoration after brain injury, and to evaluate how tumor cells co-opt axonogenic programs for malignancy. Because axonogenesis is a morphogenetic process, its experimental dissection requires models that can test causal gene function, which is why CRISPR-based knockout, point-mutation, knock-in, and overexpression approaches are increasingly central to the field.
axonogenesis At A Glance
| GO ID | GO:0007409 |
|---|---|
| GO term | axonogenesis |
| Ontology | biological_process |
| Synonym | axon growth; axon morphogenesis; neuron long process generation |
| Major function | De novo generation of a neuron's long process, including the terminal branched region, enabling efferent action potential transmission from the cell body toward target cells |
| Process type | Neuronal morphogenesis / developmental process |
| Cellular context | Neuron cell body and extending axon, including terminal branches |
| Disease relevance | Tumor progression and aggressiveness in adenoid cystic carcinoma, KRAS-mutant pancreatic cancer, and osteosarcoma; neuronal restoration after brain injury |
| Key regulator example | PTBP2, a neuron-specific splicing regulator that coordinates axonogenesis |
What Is GO:0007409?
According to the QuickGO definition, axonogenesis (GO:0007409) is the de novo generation of a long process of a neuron, including the terminal branched region. It refers to the morphogenesis or creation of shape or form of the developing axon, which carries efferent (outgoing) action potentials from the cell body towards target cells. In other words, axonogenesis is the process of building an axon from scratch, encompassing its initial outgrowth and the formation of its terminal branches, rather than simply maintaining or regenerating an existing axon.
Why Is axonogenesis Important in Cell Biology?
Axonogenesis is important because it establishes the structural foundation of neuronal connectivity, and its dysregulation or reactivation is linked to both neurological injury responses and cancer progression. The process is coordinated by neuron-specific alternative splicing programs, as shown for PTBP2, and is supported by neuroimmune signals such as CCL5 during neuronal restoration after brain injury. In cancer, axonogenesis is co-opted by tumors including adenoid cystic carcinoma, KRAS-mutant pancreatic cancer, and osteosarcoma to promote progression and aggressiveness. Environmental factors such as the maternal microbiome also modulate fetal neurodevelopment in mice, underscoring the broad relevance of axonogenesis to development, regeneration, and disease.
• Axonogenesis is the developmental process that builds the axon, the neuron's output cable for efferent action potentials, as defined by QuickGO.
• Neuron-specific alternative splicing programming, including the splicing regulator PTBP2, coordinates axonogenesis.
• CCL5 is essential for axonogenesis and neuronal restoration after brain injury, linking neuroimmune signaling to axonal regrowth.
• Sympathetic axonogenesis promotes adenoid cystic carcinoma progression.
• Endosomal trafficking bypassed by RAB5B-CD109 interplay promotes axonogenesis in KRAS-mutant pancreatic cancer.
• Mesenchymal stroma drives axonogenesis and nerve-induced aggressiveness in osteosarcoma.
• Tumor lineage plasticity in neuroendocrine prostate cancer can be therapeutically targeted by BRD4 inhibitors, a context relevant to axonogenesis-related programs.
• Peripheral, central, and chemotherapy-induced neuropathic changes occur in pancreatic cancer, highlighting nerve-tumor interactions.
• The maternal microbiome modulates fetal neurodevelopment in mice, including axonogenesis-related processes.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of axonogenesis genes.
What Happens During axonogenesis?
Initiation and specification of the axon
In simple terms: A neuron decides which of its short processes will become the long axon and starts to grow it.
Axonogenesis begins with the de novo generation of a long process from the neuron, as defined by QuickGO. This early phase is coordinated by neuron-specific alternative splicing programs; the splicing regulator PTBP2 controls the timing and fidelity of axon outgrowth, ensuring that the developing neuron produces the correct repertoire of axonogenic transcripts. The process is thus not a default extension but a regulated morphogenetic program that specifies the axon among neuronal processes.
Elongation and terminal branching
In simple terms: The axon gets longer and forms branches at its end to reach multiple targets.
Following initiation, the axon elongates and forms its terminal branched region, which is explicitly included in the QuickGO definition of axonogenesis. This phase requires coordinated membrane and cytoskeletal dynamics, and it is influenced by extrinsic signals. For example, CCL5 is essential for axonogenesis and neuronal restoration after brain injury, supporting the elongation and re-establishment of neuronal processes in a regenerative context. The terminal branched region is the structural endpoint of axonogenesis and is critical for target innervation.
Neuron-specific alternative splicing control
In simple terms: A molecular editor called PTBP2 helps the neuron produce the right protein versions needed for axon growth.
Axonogenesis is coordinated by neuron-specific alternative splicing programming and splicing regulator PTBP2. This means that the process depends not only on transcriptional activation of axonogenic genes but also on post-transcriptional splicing decisions that generate neuron-specific isoforms. PTBP2 acts as a key regulator that couples the splicing program to the morphogenetic execution of axon outgrowth.
Neuroimmune and environmental modulation
In simple terms: Signals from the immune system and the environment can influence how axons grow.
Axonogenesis is modulated by neuroimmune signals and environmental factors. CCL5 is essential for axonogenesis and neuronal restoration after brain injury, demonstrating that immune-related chemokines can promote axonal regrowth. In addition, the maternal microbiome modulates fetal neurodevelopment in mice, indicating that environmental inputs during development can shape axonogenesis-related processes. These findings place axonogenesis within a broader physiological context beyond intrinsic neuronal programs.
Pathological reactivation in cancer
In simple terms: Tumors can switch on axon-growth programs to become more aggressive.
Axonogenesis is reactivated in several cancers, where it promotes tumor progression. Sympathetic axonogenesis promotes adenoid cystic carcinoma progression, and endosomal trafficking bypassed by the RAB5B-CD109 interplay promotes axonogenesis in KRAS-mutant pancreatic cancer. Mesenchymal stroma drives axonogenesis and nerve-induced aggressiveness in osteosarcoma. These examples show that the axonogenesis program can be co-opted by malignant cells and their microenvironment, making it a potential therapeutic target.
Key Genes Involved in GO:0007409 axonogenesis
The following genes and proteins have been experimentally implicated in axonogenesis or in its pathological reactivation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTBP2 | Neuron-specific splicing regulator coordinating axonogenesis | Central regulator of alternative splicing programs required for axon outgrowth |
| CCL5 | Chemokine essential for axonogenesis and neuronal restoration after brain injury | Links neuroimmune signaling to axonal regrowth and repair |
| RAB5B | Endosomal trafficking protein promoting axonogenesis in KRAS-mutant pancreatic cancer | Mediates endosomal trafficking bypass that supports tumor axonogenesis |
| CD109 | Interacts with RAB5B to promote axonogenesis in KRAS-mutant pancreatic cancer | Part of the RAB5B-CD109 interplay driving axonogenesis |
| KRAS | Mutant oncogene context in which axonogenesis is promoted | Defines the genetic background of pancreatic cancer axonogenesis |
| BRD4 | Target of inhibitors that reverse tumor lineage plasticity in neuroendocrine prostate cancer | Relevant to lineage plasticity programs that may intersect with axonogenesis |
| Sympathetic neuron genes (adenoid cystic carcinoma context) | Drive sympathetic axonogenesis promoting tumor progression | Model for nerve-tumor interactions in adenoid cystic carcinoma |
| Mesenchymal stroma-derived factors (osteosarcoma context) | Drive axonogenesis and nerve-induced aggressiveness | Model for stromal-nerve crosstalk in osteosarcoma |
| Maternal microbiome-associated factors | Modulate fetal neurodevelopment including axonogenesis-related processes | Environmental modifier of developmental axonogenesis in mice |
| Pancreatic cancer neuropathy-associated genes | Contribute to peripheral, central, and chemotherapy-induced neuropathic changes | Relevant to nerve changes in pancreatic cancer |
| Neuroendocrine prostate cancer lineage plasticity genes | Mediate lineage plasticity targetable by BRD4 inhibitors | Context for axonogenesis-related plasticity programs |
| Adenoid cystic carcinoma progression genes | Promote tumor progression via sympathetic axonogenesis | Model for sympathetic axonogenesis in cancer |
| Osteosarcoma aggressiveness genes | Mediate nerve-induced aggressiveness driven by mesenchymal stroma | Model for stroma-driven axonogenesis |
| Brain injury repair genes | Support neuronal restoration after brain injury | Context for CCL5-dependent axonogenesis |
| Fetal neurodevelopment genes | Regulate neurodevelopment in response to maternal microbiome | Developmental context for axonogenesis |
| Chemotherapy-induced neuropathy genes | Mediate neuropathic changes in pancreatic cancer | Context for nerve damage and repair |
How Is axonogenesis Regulated?
Axonogenesis is regulated at multiple levels. At the post-transcriptional level, neuron-specific alternative splicing programming and the splicing regulator PTBP2 coordinate the process, ensuring that the correct isoforms are produced during axon outgrowth. At the signaling level, CCL5 is essential for axonogenesis and neuronal restoration after brain injury, indicating that chemokine signaling can promote axonal regrowth. In cancer, axonogenesis is regulated by endosomal trafficking pathways, as shown by the RAB5B-CD109 interplay that promotes axonogenesis in KRAS-mutant pancreatic cancer, and by stromal signals from the mesenchymal compartment that drive axonogenesis and nerve-induced aggressiveness in osteosarcoma. Tumor lineage plasticity programs, which can be targeted by BRD4 inhibitors in neuroendocrine prostate cancer, may also intersect with axonogenic regulatory networks. Environmental factors such as the maternal microbiome further modulate fetal neurodevelopment in mice, adding an extrinsic layer of regulation.
axonogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTBP2 | Axonogenesis coordination via neuron-specific alternative splicing | Knockout and point-mutation models to test splicing-dependent axon outgrowth |
| CCL5 | Brain injury and neuronal restoration | Knockout and overexpression models to test CCL5-dependent axonogenesis |
| RAB5B / CD109 | KRAS-mutant pancreatic cancer | Knockout and knock-in models to dissect endosomal trafficking in axonogenesis |
| BRD4 | Neuroendocrine prostate cancer lineage plasticity | Point-mutation and overexpression models to test BRD4 inhibitor sensitivity |
| Mesenchymal stroma factors | Osteosarcoma aggressiveness | Knock-in and overexpression models to test stroma-driven axonogenesis |
Axonogenesis in cancer progression
Axonogenesis is reactivated in multiple cancers and contributes to tumor progression. Sympathetic axonogenesis promotes adenoid cystic carcinoma progression. In KRAS-mutant pancreatic cancer, endosomal trafficking bypassed by the RAB5B-CD109 interplay promotes axonogenesis. Mesenchymal stroma drives axonogenesis and nerve-induced aggressiveness in osteosarcoma. These findings establish axonogenesis as a pathological process in the tumor microenvironment and a potential target for therapeutic intervention.
Axonogenesis and neuronal restoration after brain injury
CCL5 is essential for axonogenesis and neuronal restoration after brain injury. This links axonogenesis to neuroregeneration and suggests that chemokine-mediated signaling could be harnessed to promote axonal regrowth after injury. The study provides direct evidence that axonogenesis is not limited to development but can be reactivated in the injured brain.
Axonogenesis, neuropathy, and tumor lineage plasticity
Peripheral, central, and chemotherapy-induced neuropathic changes occur in pancreatic cancer, highlighting the clinical importance of nerve changes in cancer patients. In neuroendocrine prostate cancer, tumor lineage plasticity can be effectively targeted by BRD4 inhibitors, a finding relevant to plasticity programs that may overlap with axonogenic gene networks. Together, these studies indicate that axonogenesis-related biology intersects with neuropathy and lineage plasticity in human disease.
Developmental axonogenesis and environmental modulation
The maternal microbiome modulates fetal neurodevelopment in mice, demonstrating that developmental axonogenesis-related processes are sensitive to environmental inputs. This has implications for understanding how early-life exposures shape neuronal wiring and may influence susceptibility to neurodevelopmental disorders.
From axonogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is PTBP2 causally required for axonogenesis? | PTBP2 knockout and point-mutation cell models |
| Does CCL5 promote neuronal restoration after brain injury? | CCL5 knockout and overexpression models |
| Does RAB5B-CD109 interplay drive axonogenesis in KRAS-mutant pancreatic cancer? | RAB5B and CD109 knockout and knock-in models |
| Does mesenchymal stroma drive axonogenesis in osteosarcoma? | Stroma-derived factor overexpression and knockout models |
| Can BRD4 inhibition reverse lineage plasticity? | BRD4 point-mutation and overexpression models |
| How does the maternal microbiome influence fetal neurodevelopment? | In vivo mouse models with microbiome manipulation |
How to Study the axonogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript abundance and splicing changes | Identifying axonogenesis-associated isoforms and PTBP2-dependent splicing |
| Imaging of axonal morphology | Axon length, branching, and terminal region formation | Quantifying axonogenesis in neurons and tumor models |
| Co-culture assays | Stroma-to-tumor signaling effects | Testing mesenchymal stroma-driven axonogenesis in osteosarcoma |
| Brain injury models | Neuronal restoration and axon regrowth | Evaluating CCL5-dependent axonogenesis after injury |
| Endosomal trafficking assays | RAB5B-CD109 interplay and trafficking bypass | Dissecting axonogenesis in KRAS-mutant pancreatic cancer |
| Lineage plasticity assays | Tumor lineage plasticity and drug response | Testing BRD4 inhibitor effects in neuroendocrine prostate cancer |
| Microbiome manipulation in mice | Fetal neurodevelopment outcomes | Studying maternal microbiome effects on axonogenesis |
| Neuropathy assessment | Peripheral and central neuropathic changes | Characterizing nerve changes in pancreatic cancer |
Transcriptomic and splicing analysis
Because axonogenesis is coordinated by neuron-specific alternative splicing programming and PTBP2, RNA-seq and splicing-sensitive analyses are essential to identify axonogenic isoforms and splicing events. These methods allow researchers to compare splicing patterns between control and perturbed neurons or tumor cells, revealing how PTBP2 and other regulators shape the axonogenesis transcriptome.
Imaging of axonal morphology
Axonogenesis is a morphogenetic process defined by the de novo generation of a long process and its terminal branched region. Imaging-based assays are therefore central to measuring axon length, branching, and morphology. Such approaches are used to quantify axon outgrowth in neurons and to assess axonogenesis-like structures in tumor models, including adenoid cystic carcinoma and osteosarcoma.
Tumor microenvironment and co-culture assays
Because mesenchymal stroma drives axonogenesis and nerve-induced aggressiveness in osteosarcoma, co-culture and microenvironment modeling methods are important. These assays test how stromal cells and their secreted factors influence axonogenesis in tumor cells, and they can be combined with genetic perturbation to identify causal mediators.
Neuroimmune and injury models
CCL5 is essential for axonogenesis and neuronal restoration after brain injury, so injury models and neuroimmune assays are used to study axonogenesis in repair contexts. These methods measure neuronal restoration and axon regrowth after injury and can be coupled with chemokine perturbation to define mechanisms.
How CRISPR Can Be Used to Study GO:0007409 axonogenesis
Knockout
CRISPR knockout is used to test whether candidate genes are causally required for axonogenesis. For example, knocking out PTBP2 would test its role in neuron-specific alternative splicing programming and axon outgrowth, while knocking out CCL5 would test its essential function in axonogenesis and neuronal restoration after brain injury. Knockout of RAB5B or CD109 would test the RAB5B-CD109 interplay in KRAS-mutant pancreatic cancer axonogenesis.
Point Mutation
CRISPR point-mutation models introduce specific amino acid changes to dissect domain functions without eliminating the protein. This is useful for testing whether particular residues in splicing regulators such as PTBP2 are required for axonogenesis, or whether specific domains of RAB5B and CD109 mediate endosomal trafficking bypass in KRAS-mutant pancreatic cancer. Point mutations can also model clinically relevant variants in axonogenesis-related genes.
Knock-in
CRISPR knock-in enables precise insertion of tags, reporters, or disease-relevant alleles. Tagged knock-in of axonogenesis genes allows visualization of protein localization during axon outgrowth, while knock-in of mutant alleles can model disease-associated changes. This approach is applicable to genes such as PTBP2, CCL5, and RAB5B/CD109, and to lineage plasticity genes targeted by BRD4 inhibitors.
Overexpression
CRISPR overexpression models test gain-of-function effects and are particularly relevant for axonogenesis factors that promote tumor progression. Overexpression of CCL5 can test whether increased chemokine signaling enhances axonogenesis and neuronal restoration, while overexpression of RAB5B or CD109 can test whether these factors are sufficient to promote axonogenesis in KRAS-mutant pancreatic cancer. Overexpression of mesenchymal stroma-derived factors can test their sufficiency in driving osteosarcoma axonogenesis.
How EDITGENE Supports axonogenesis Research
Researchers studying axonogenesis-related genes often need to determine whether a candidate gene is causally involved in axon outgrowth, terminal branching, or pathological reactivation in cancer. Establishing causality requires precise genetic models that can eliminate, modify, tag, or overexpress the gene of interest in relevant cellular contexts. EDITGENE provides a comprehensive suite of CRISPR-based services designed to support such studies, from knockout and point-mutation models to knock-in reporters and overexpression lines, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for axonogenesis research.
Frequently Asked Questions About axonogenesis
What is GO:0007409 axonogenesis?
GO:0007409 axonogenesis is the biological process of de novo generation of a long process of a neuron, including the terminal branched region, as defined by QuickGO. It refers to the morphogenesis or creation of shape or form of the developing axon, which carries efferent action potentials from the cell body towards target cells.
What genes are involved in axonogenesis?
Genes experimentally implicated in axonogenesis include PTBP2, a neuron-specific splicing regulator that coordinates axonogenesis, and CCL5, which is essential for axonogenesis and neuronal restoration after brain injury. In cancer contexts, RAB5B and CD109 promote axonogenesis in KRAS-mutant pancreatic cancer, and mesenchymal stroma drives axonogenesis in osteosarcoma.
How is axonogenesis regulated?
Axonogenesis is regulated by neuron-specific alternative splicing programming and the splicing regulator PTBP2, by chemokine signaling such as CCL5 after brain injury, and by endosomal trafficking pathways involving RAB5B and CD109 in KRAS-mutant pancreatic cancer. Stromal signals also regulate axonogenesis in osteosarcoma.
Is axonogenesis involved in cancer?
Yes. Sympathetic axonogenesis promotes adenoid cystic carcinoma progression, endosomal trafficking bypassed by RAB5B-CD109 interplay promotes axonogenesis in KRAS-mutant pancreatic cancer, and mesenchymal stroma drives axonogenesis and nerve-induced aggressiveness in osteosarcoma.
What is the role of PTBP2 in axonogenesis?
PTBP2 is a neuron-specific splicing regulator that coordinates axonogenesis through alternative splicing programming, controlling the production of isoforms required for axon outgrowth.
How does CCL5 affect axonogenesis?
CCL5 is essential for axonogenesis and neuronal restoration after brain injury, indicating that this chemokine supports axonal regrowth in the injured brain.
What happens during axonogenesis?
During axonogenesis, a neuron generates a long process de novo, including its terminal branched region, as defined by QuickGO. This process is coordinated by neuron-specific alternative splicing programs and can be modulated by neuroimmune signals such as CCL5.
How can I study axonogenesis with CRISPR?
CRISPR knockout can test whether genes such as PTBP2 or CCL5 are required for axonogenesis, while point-mutation, knock-in, and overexpression models can dissect domain functions, visualize proteins, and test sufficiency. EDITGENE provides these services along with library screening and bioinformatics.
What diseases are linked to axonogenesis?
Axonogenesis is linked to adenoid cystic carcinoma progression, KRAS-mutant pancreatic cancer, osteosarcoma aggressiveness, brain injury and neuronal restoration, and neuroendocrine prostate cancer lineage plasticity. Pancreatic cancer also shows peripheral, central, and chemotherapy-induced neuropathic changes.
Does the maternal microbiome affect axonogenesis?
The maternal microbiome modulates fetal neurodevelopment in mice, indicating that environmental factors can influence axonogenesis-related processes during development.
Conclusion
GO:0007409 axonogenesis is the de novo generation of a neuron's long process, including its terminal branched region, and it is coordinated by neuron-specific alternative splicing programs such as PTBP2. The process is essential for neuronal connectivity and can be reactivated in disease, including adenoid cystic carcinoma, KRAS-mutant pancreatic cancer, and osteosarcoma, as well as in neuronal restoration after brain injury through CCL5. Studying axonogenesis requires precise genetic models, and CRISPR-based knockout, point-mutation, knock-in, and overexpression approaches, together with library screening and bioinformatics, provide the tools needed to establish causal gene function. EDITGENE supports these efforts with tailored services for axonogenesis research.
References
- 1. Chen CH et al.. 2025. Sympathetic axonogenesis promotes adenoid cystic carcinoma progression.. J Exp Med 222(7) PMID: 40272482
- 2. Ho MH et al.. 2024. CCL5 is essential for axonogenesis and neuronal restoration after brain injury.. J Biomed Sci 31(1):91 PMID: 39285280
- 3. Zhang D et al.. 2024. Endosomal Trafficking Bypassed by the RAB5B-CD109 Interplay Promotes Axonogenesis in KRAS-Mutant Pancreatic Cancer.. Adv Sci (Weinh) 11(47):e2405092 PMID: 39488792
- 4. Di Pompo G et al.. 2025. Mesenchymal stroma drives axonogenesis and nerve-induced aggressiveness in osteosarcoma.. J Exp Clin Cancer Res 44(1):276 PMID: 41029717
- 5. Zhang X et al.. 2025. Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors.. Acta Pharm Sin B 15(3):1415-1429 PMID: 40370549
- 6. Zhang M et al.. 2019. Axonogenesis Is Coordinated by Neuron-Specific Alternative Splicing Programming and Splicing Regulator PTBP2.. Neuron 101(4):690-706.e10 PMID: 30733148
- 7. Jiang L et al.. 2025. Peripheral, central, and chemotherapy-induced neuropathic changes in pancreatic cancer.. Trends Neurosci 48(2):124-139 PMID: 39730257
- 8. Vuong HE et al.. 2020. The maternal microbiome modulates fetal neurodevelopment in mice.. Nature 586(7828):281-286 PMID: 32968276
